Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Conte

Showing results (91-100 of 200) with videos related to

Pageof 20
Sort By:
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy|April 1, 1985
High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary resultsM Bruzzone, P F Conte, S Chiara, et al.
American Journal of Clinical Oncology|August 24, 2000
Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumorsS Ricci, A Antonuzzo, L Galli, et al.
British Journal of Cancer|May 20, 2004
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) groupA Buda, I Floriani, R Rossi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 1, 1991
Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancerS Chiara, M Orsatti, P Franzone, et al.
Giornale Italiano Di Chemioterapia|January 1, 1985
[Adjuvant chemotherapy with cisplatin and cyclophosphamide in FIGO I-II epithelial carcinoma of the ovary: preliminary results]S Chiara, P F Conte, M Bruzzone, et al.
Gynecologic Oncology|September 1, 1990
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second lookM Bruzzone, L Repetto, S Chiara, et al.
Tumori|June 30, 1990
Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimensL Repetto, S Chiara, M Pace, et al.
Bone Marrow Transplantation|July 27, 2004
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell supportV Guarneri, C Bengala, C Orlandini, et al.
Seminars in Oncology|October 1, 1996
Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patientsA Michelotti, A Gennari, B Salvadori, et al.
Gynecologic Oncology|June 12, 2003
First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patientsA Romanini, L Tanganelli, F Carnino, et al.
Pageof 20

Showing results (91-100 of 200) with videos related to

Sort By:
Pageof 20
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy|April 1, 1985
High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary resultsM Bruzzone, P F Conte, S Chiara, et al.
American Journal of Clinical Oncology|August 24, 2000
Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumorsS Ricci, A Antonuzzo, L Galli, et al.
British Journal of Cancer|May 20, 2004
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) groupA Buda, I Floriani, R Rossi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 1, 1991
Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancerS Chiara, M Orsatti, P Franzone, et al.
Giornale Italiano Di Chemioterapia|January 1, 1985
[Adjuvant chemotherapy with cisplatin and cyclophosphamide in FIGO I-II epithelial carcinoma of the ovary: preliminary results]S Chiara, P F Conte, M Bruzzone, et al.
Gynecologic Oncology|September 1, 1990
Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second lookM Bruzzone, L Repetto, S Chiara, et al.
Tumori|June 30, 1990
Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimensL Repetto, S Chiara, M Pace, et al.
Bone Marrow Transplantation|July 27, 2004
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell supportV Guarneri, C Bengala, C Orlandini, et al.
Seminars in Oncology|October 1, 1996
Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patientsA Michelotti, A Gennari, B Salvadori, et al.
Gynecologic Oncology|June 12, 2003
First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patientsA Romanini, L Tanganelli, F Carnino, et al.
Pageof 20